Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE.

Science. 1993 Jul 9;261(5118):212-5. Erratum in: Science 1994 Feb 25;263(5150):1076.

PMID:
8327892
2.
3.

In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.

Siegall CB, Chace D, Mixan B, Garrigues U, Wan H, Paul L, Wolff E, Hellström I, Hellström KE.

J Immunol. 1994 Mar 1;152(5):2377-84.

PMID:
8133048
4.

Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.

Trail PA, Willner D, Bianchi AB, Henderson AJ, TrailSmith MD, Girit E, Lasch S, Hellström I, Hellström KE.

Clin Cancer Res. 1999 Nov;5(11):3632-8.

5.

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

Remsen LG, Trail PA, Hellström I, Hellström KE, Neuwelt EA.

Neurosurgery. 2000 Mar;46(3):704-9.

PMID:
10719867
6.

Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR.

Cancer Res. 1992 Oct 15;52(20):5693-700.

7.

Development and activities of the BR96-doxorubicin immunoconjugate.

Hellström I, Hellström KE, Senter PD.

Methods Mol Biol. 2001;166:3-16. Review. No abstract available.

PMID:
11217374
8.
9.

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.

Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.

Cancer Res. 1997 Jan 1;57(1):100-5.

10.

Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model.

Remsen LG, Marquez C, Garcia R, Thrun LA, Neuwelt EA.

Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1045-9.

PMID:
11704329
11.

Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin.

Desrues B, Léna H, Brichory F, Ramée MP, Toujas L, Delaval P, Dazord L.

Br J Cancer. 1995 Nov;72(5):1076-82.

12.

Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.

Friedman PN, Chace DF, Trail PA, Siegall CB.

J Immunol. 1993 Apr 1;150(7):3054-61.

PMID:
8454873
13.
14.

Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens.

Hellström I, Garrigues HJ, Garrigues U, Hellström KE.

Cancer Res. 1990 Apr 1;50(7):2183-90.

15.

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.

Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, LoBuglio AF.

J Clin Oncol. 2000 Jun;18(11):2282-92.

PMID:
10829049
16.
17.

BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models.

Muldoon LL, Neuwelt EA.

J Neurooncol. 2003 Oct;65(1):49-62.

PMID:
14649885
18.

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.

Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W.

J Clin Oncol. 1999 Feb;17(2):478-84.

PMID:
10080588
19.

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.

Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA.

Bioconjug Chem. 2002 Jul-Aug;13(4):855-69.

PMID:
12121142
20.

Supplemental Content

Support Center